Oleptro Side Effects
Generic name: trazodone
Note: This document contains side effect information about trazodone. Some of the dosage forms listed on this page may not apply to the brand name Oleptro.
Some side effects of Oleptro may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to trazodone: oral tablet, oral tablet extended release
Along with its needed effects, trazodone (the active ingredient contained in Oleptro) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking trazodone:More common
- Blurred vision
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- unusual tiredness or weakness
- Burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
- confusion about identity, place, and time
- decreased concentration
- general feeling of discomfort or illness
- lack of coordination
- muscle tremors
- pounding in the ears
- shortness of breath
- slow or fast heartbeat
- Skin rash
- unusual excitement
Some side effects of trazodone may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- Dry mouth (usually mild)
- muscle or bone pain
- trouble sleeping
- trouble with remembering
- unpleasant taste
- continuing ringing or buzzing or other unexplained noise in the ears
- hearing loss
- muscle aches or pains
- weight loss
For Healthcare Professionals
Applies to trazodone: compounding powder, oral tablet, oral tablet extended release
Nervous system side effects are common and include drowsiness and sedation in as many as 50% of treated patients. Dizziness (10% to 30%), sleep abnormalities, headache, fatigue and, more rarely, seizures, dystonia, akathisia, myoclonus, palinopsia (persistence or reappearance of an image of a recently viewed object), and extrapyramidal symptoms have been reported. One case of serotonin syndrome has been reported which is believed to have been precipitated by the combination of venlafaxine and trazodone (the active ingredient contained in Oleptro)
Nearly all selective serotonin reuptake inhibitors, mixed serotonin/norepinephrine reuptake inhibitors, and tricyclic antidepressants cause sleep abnormalities to some extent. These antidepressants have marked dose-dependent effects on rapid eye movement (REM) sleep, causing reductions in the overall amount of REM sleep over the night and delays the first entry into REM sleep (increased REM sleep onset latency (ROL)), both in healthy subjects and depressed patients. The antidepressants that increase serotonin function appear to have the greatest effect on REM sleep. The reduction in REM sleep is greatest early in treatment, but gradually returns towards baseline during long-term therapy; however, ROL remains long. Following discontinuation of therapy the amount of REM sleep tends to rebound. Some of these drugs (i.e., bupropion, mirtazapine, nefazodone, trazodone, trimipramine) appear to have a modest or minimal effect on REM sleep.
Psychiatric side effects have been reported and include mania, paranoia, hypomania (during and following therapy), increased libido, delirium, agitation, psychosis, hallucinations and self- destructive behavior.
Cardiovascular side effects including arrhythmias, hypotension, peripheral edema, postural hypotension, ventricular ectopy, ventricular tachycardia, torsades de pointes, rapid atrial fibrillation, heart block, and other conduction abnormalities have been reported.
Some investigators have suggested that trazodone exerts fewer adverse cardiovascular effects than many other antidepressants.
Genitourinary side effects including priapism, clitoral priapism, ejaculatory inhibition, and anorgasmia have been reported.
Priapism has been rarely reported (0.01% to 0.1%). Priapism has occurred with doses of 50 to 150 mg daily and typically within the first 28 days of treatment. Approximately one-third of affected individuals have required surgical intervention. It has been suggested that trazodone's alpha-adrenergic blocking properties may contribute to the induction of priapism.
One case of spontaneous orgasms in an elderly postmenopausal woman has also been reported.
Anticholinergic (and possibly alpha-adrenergic blocking) side effects have been reported, although much less frequently than with many other antidepressants. The effects reported include dry mouth, blurred vision, constipation, and urinary retention.
Hepatic side effects including cases of chronic active hepatitis and drug-induced hepatotoxicity have been reported rarely.
One case of severe hepatotoxicity followed a four day course of trazodone therapy.
Dermatologic side effects including erythema multiforme, leukocytoclastic vasculitis, pustular psoriasis, drug eruptions, and acute peripheral edema have been reported rarely.
Hematologic side effects have included alterations in laboratory studies such as significant decreases in hematocrit, hemoglobin, red blood cell count, serum cholesterol, serum calcium, and serum albumin levels. Pseudoanemia (laboratory findings suggestive of anemia without pathologic significance) has been reported in 36% of treated patients.
Endocrine side effects have included hyperprolactinemia and hyponatremia (in association with the syndrome of inappropriate secretion of antidiuretic hormone).
Gastrointestinal side effects have included dry mouth (up to 34%) and constipation.
More Oleptro resources
- Oleptro Prescribing Information (FDA)
- Oleptro Consumer Overview
- Oleptro Advanced Consumer (Micromedex) - Includes Dosage Information
- Oleptro extended-release tablets MedFacts Consumer Leaflet (Wolters Kluwer)
- Desyrel MedFacts Consumer Leaflet (Wolters Kluwer)
- Desyrel Prescribing Information (FDA)
- Trazodone Prescribing Information (FDA)
- Trazodone Hydrochloride Monograph (AHFS DI)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.